Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27062672 | 0.98 | FAAH (0.33) | FAAHRELAKDM4EHPGDEPHX1 | |
| SCHEMBL19257094 | 0.86 | EPHX1 (0.37) | FAAHEPHX1CA2PPARAGGPS1 | |
| SCHEMBL19271990 | 0.81 | EPHX1 (0.36) | FAAHEPHX1CA2PPARAGGPS1 | |
| SCHEMBL19352779 | 0.79 | EPHX1 (0.37) | FAAHEPHX1CA2PPARAGGPS1 | |
| SCHEMBL19271944 | 0.76 | HPGD (0.35) | FAAHHPGDEPHX1PPARAGGPS1 | |
| SCHEMBL2630537 | 0.76 | HPGD (0.40) | FAAHRELAKDM4EHPGDEPHX1 | |
| SCHEMBL21362003 | 0.76 | PPARA (0.38) | FAAHEPHX1CA2PPARAGGPS1 | |
| SCHEMBL19287438 | 0.75 | EPHX1 (0.33) | FAAHEPHX1PPARAGGPS1 | |
| SCHEMBL20033752 | 0.75 | ALDH1A1 (0.38) | FAAHRELAKDM4EHPGDCA2 | |
| SCHEMBL19257391 | 0.74 | HPGD (0.36) | FAAHHPGDEPHX1PPARAGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | FAAH 4576/4885RELA 966/4885KDM4E 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.